A Phase III, Randomised, Double-blind, Parallel Group, 52 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin and Linagliptin Fixed Dose Combination Compared With Linagliptin Plus Placebo in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control After 16 Weeks Treatment With Once Daily Linagliptin 5 mg.
Phase of Trial: Phase III
Latest Information Update: 26 May 2017
At a glance
- Drugs Empagliflozin/linagliptin (Primary) ; Linagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 10 Jun 2017 Biomarkers information updated
- 22 May 2017 Status changed from active, no longer recruiting to completed.
- 11 Apr 2016 Status changed from recruiting to active, no longer recruiting.